Prelude Therapeutics | 8-K: Current report
Prelude Therapeutics | 10-Q: Q2 2024 Earnings Report
Prelude Therapeutics | 8-K: Prelude Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Prelude Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Huang Jane
Prelude Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director BAKER BROS. ADVISORS LP
Prelude Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Bonita David P
Prelude Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Sandor Victor
Prelude Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director FRIEDMAN PAUL A
Prelude Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Dier Mardi
Prelude Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Babler Martin
Prelude Therapeutics | 8-K: Current report
Prelude Therapeutics | 8-K: Current report
Prelude Therapeutics | EFFECT: Others
Prelude Therapeutics | CORRESP: CORRESP
Prelude Therapeutics | UPLOAD: Others
Prelude Therapeutics | S-3: Registration statement for specified transactions by certain issuers
Prelude Therapeutics | 8-K/A: Current report (Amendment)
Prelude Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Lim Bryant David
Prelude Therapeutics | EFFECT: Others
Prelude Therapeutics | 10-Q: Q1 2024 Earnings Report
No Data